Q3 2021 Colfax Corp Earnings Call

[music].

Welcome to the Colfax third quarter 2021 earnings call. My name is in that and I'll be your operator for today's call. At this time, all participants are in and as listen only mode. Later, we will conduct.

The question and answer session. During the Q&A session. If you have a question. Please press Star then one on your Touchtone phone I will now turn the call over to Mike Mason. Mr. Mason you may begin.

Good morning, everyone and thank you for joining us I'm, Mike Basic Vice President of Finance joining me on the call today are metrocorp, President and CEO, Sean Combo, Yonder Executive Vice President and CEO of Aesop, and Chris Hix Executive Vice President and CFO.

Our earnings release was issued earlier this morning and is available in the investors section of our website Colfax Corp Dot com.

We're using a slide presentation to walk through today's call, which can also be found on our website. Both the audio and the slide presentation of this call will be archived on the website later today and will be available until the next quarterly earnings call.

During this call, we'll be making some forward looking statements about our beliefs and estimates regarding future events and results. These forward looking statements are subject to risks and uncertainties, including those set forth in our safe Harbor language in today's earnings release and in our filings with the SEC.

Actual results might differ materially from any forward looking statements that we make today are forward looking statements speak only as of today and we do not assume any obligation or intend to update them, except as required by law with respect to any non-GAAP financial measures made during the call today. The accompanying reconciliation information related to those measures can be.

We found in our earnings press release, and today's slide presentation with that let me turn it over to Matt who will start on slide three.

Thanks, Mike welcome everyone and thanks for joining our call today I'm pleased to report that our business has performed well in the quarter and we made strong progress on key strategic priorities.

Our third quarter commitments by drawing organic revenues, 15% and achieving adjusted EPS growth of 32%. Despite the challenging environment. We also outperformed our markets as a result of our amazing teams around the world I want to take a moment to thank our teams for their continued dedication to our customers and patients and to the success of our <unk>.

<unk>.

<unk> exceeded our expectations this quarter with better than expected growth and strong margin expansion. We continue to see strong execution here and as a result, we're increasing our full year organic growth and margin expectations outlook for Aesop I've asked John <unk>, the CEO of SaaS to join the call. This morning to talk further about this.

<unk> performance and progress.

Med Tech performed well given the given the challenges faced by the industry.

We outperformed the market in both PNR and recon again, but were impacted by Covid, driven slowing of illiquid elective procedures, which I'll touch on more in a few minutes.

We're making strong progress integrating the recent acquisitions and I'll share. Some highlights later in the call.

Finally, we are fully on track for the expected tax free spin off of our <unk> business to Colfax shareholders.

We've made substantial progress towards creating two independent boards with relevant skills experiences and diversity and with limited overlap.

Also we filled all the key corporate leadership positions for each job with tremendous talent readying them to become an independent public company.

And as Youll see in a few moments. We've also selected our new corporate name, which symbolizes our exciting future.

We continue to target a separation for the first quarter of 2022, and we're confident that we will position both companies for maximum long term growth and value creation.

Slide four gives an update of our med tech business.

Sales for the quarter increased 14% or 1% on an organic sales per day basis. This includes a two point headwind from one time PPE sales in Q3 last year. While this is below the expectations that we had entering the quarter. We believe that is very strong top line performance given the temporary pressure on elective surgeries.

In the quarter.

The key thing to note is that both businesses recon and PNR continue to outperform their markets.

We've grown well ahead of peers for a number of periods over the past several years.

The year to date organic growth figures versus 2019 on the slide tell the story.

Our recon business is up 7% year to date versus 2019, and our PNR business is approximately flat these are organic numbers.

Both significantly better than market rates.

And recon, our shoulder implants grew double digits year to date versus 2019, continuing to take share through innovation and commercial execution.

As we move past Covid and returned to normalized market growth both of our med Tech businesses are well positioned to show strong growth in 2022 and consistent market outperformance over time.

In the quarter, we had some unexpected impact from Covid primarily in recon.

After a strong June and July we saw a slowing of elective procedures in certain regions of the U S. However.

However, we did see improvement in October, giving us confidence in our expectation of gradual improvement in Q4.

This points to a more normal market environment in 2022, and an opportunity to recapture some of the missed demand from 2020 in 2021 as pressure on hospital space and staffing subsides.

Additionally, during the quarter, we continued to see med tech supply chain inflation and inefficiencies.

Our teams are doing what it takes to serve our customers, which is driving costs higher and temporarily impacting our profitability.

We still made sequential progress in the quarter as organic EBITDA margins improved on lower organic volumes.

We also were able to implement some price increases to offset part of the inflation that we're seeing these took effect late this quarter and along with expected volume improvements support our guidance of sequential margin improvement in Q4.

We have other CBS initiatives driving price cost productivity and SG&A simplification to accelerate margin improvement in 2022, and we remain confident in our ability to substantially expand med Tech segment margins over time and achieve the long longer term targets outlined.

Earlier this year of 25%.

Slide five highlights two recent product introductions.

We continue to innovate, bringing clinically differentiated products to the market to broaden and strengthen our portfolio.

Having robust vitality as a key part of our strategy to drive above market organic growth.

And these two launches are good examples of us filling out our offerings for surgeons, increasing our clinical relevance and expanding our market reach.

The empower dual mobility hip system is the latest addition to the empower hip portfolio that provides surgeons a solution to treat treat a large patient group needing better joint stability.

Joe mobility is a sizable and important segment of the hip market and this launch will help us to secure additional business and existing surgeons and also attract new searches.

Next we continue to expand our robust suite of foot and ankle products with a dine in a hybrid fusion system, a member of the proprietary <unk> family of products.

The Diana hybrid features a unique design with ease of insertion and dynamic compression.

Our early results on this launch have been very positive we're exceeding our sales plans and have gotten excellent feedback from customers and our channel.

Slide six highlights the great progress we've made on the integration of the highly strategic recon acquisitions that we completed over the past year.

Along with our very successful U S surgical businesses business. These lay the foundation for sustained double digit organic growth and a much larger addressable market.

During our July earnings call, we announced the acquisition of Mathis, our highly complementary global expansion of our fast growing recon reconstructive platform.

Since then we've been rapidly integrating the business and there is great cultural fit between the two companies, we expect to accelerate <unk> growth by introducing several of our market leading products into their channel.

Together, we've already established a clear product roadmap and an aligned forecast for revenue synergies in the first half of 2022 methods will launch our alternate reverse shoulder and empower <unk> knee, which already have the required regulatory approvals. We're also working on a pipeline of other growth synergies.

Beyond growth our teams are collaborating secure a three year path to $15 million of annual savings from increased scale and operating synergies. Our early focus is on in sourcing projects that will generate savings next year.

We continue to expect this business to generate approximately $150 million of revenue in 2022 and build over time to double digit growth and accretive EBITDA margins.

Also we continue to build strong momentum in our foot and ankle platform, which was formed through three different acquisitions over the past year.

These additions established a differentiated differentiated product portfolio in high growth high gross margin foot and ankle market segment.

We combined our new foot and ankle businesses into a cohesive growth platform led by a very strong team with deep foot and ankle experience.

It allows us to create a powerful channel focused on the 10000 foot and ankle surgeons in the U S that will extend our reach and scale as we grow.

We also aligned on a combined innovation pipeline and acquisition priorities to expand our bag of clinically differentiated products to address the full foot and ankle market opportunity.

We continue to expect this business to grow rapidly and reached $100 million of revenue with accretive margins and strong double digit growth over the next three years.

And finally.

Really excited to introduce our new company name on slide seven.

<unk> and Novus symbolizes.

The powerful combination of innovation and vision fueled by our passion for continuous improvement and reinforced by our drive to deliver superior clinical outcomes as we strategically pivot to a specialty med Tech company focused on creating solutions that improve lives. The novus brand emphasizes the differentiated value and accretive to fore sight.

We will bring to health care professionals and their patients around the world.

And in recognition recognition of our successful history of growth and innovation the distinctive O in the new <unk> logo with delivery deliberately carried over from the Colfax logo as it represents continuous improvement the cornerstone of compounding value creation that we will continue as he novus with.

That I will turn it over to Sean who will start on slide eight.

Good morning, everyone. Thank you, Matt we had a strong quarter at Aesop and I'm proud of the progress and effort by the team.

I want to share a few things before we get into slide eight recently, we celebrated 117 <unk> as a company are fashion and committed associates are looking forward to shaping the future of fabrication technology for many years to come.

We are outpacing our end markets and further expanding our margins, reflecting strong execution by our global teams and I'm thrilled with the progress that our engineering teams are making to deliver exciting new products for our customers and I'll share more on this later.

To give you a bit more color on our end markets. We continue to experience a broad recovery across most segments, and especially strong underlying demand and infrastructure construction and renewable energy.

We're also beginning to see modest improvement in energy end markets and lastly, the one segment that continues to show some weakness as automotive as a result of the supply constraints.

Along with innovation in a broad recovery. Our next advantage is our strong global footprint.

Our footprint provides great diversification and resiliency, which has been on display during and after the pandemic.

Last and most important we continue our journey with CBS recently I had the chance to visit several of our manufacturing facilities and was especially impressed with our <unk> plan.

And its adoption of lean principles.

This facility has been and continues to be a major factor in our margin expansion and customer satisfaction journey.

Getting into the numbers.

In the third quarter total sales increased 24% versus last year, reflecting high single digit volume growth and 15 points of price.

Volume growth is fueled by our innovative products and a strong local golf game focused on customers.

Drilling down another layer third quarter volumes in the Americas rose, 11%, reflecting a strong underlying demand and continued share gain a price increase of 24% was substantially influenced by South America, The South America deemed it a fantastic job of balancing price and cost while providing best in class service to our customer.

Yes.

EMEA and APAC increased 6% versus the same period a year ago. These are strong results considering some of the regions began to rebound earlier from Goldman restriction that said, we believe our Europe business has yet to fully rebound due to weakness in the auto sector on the flip side the auto sector recovery in Europe could provide upside for <unk>.

Growth as we head into 2022.

Our GCE business continued its strong multi year growth that we.

We acquired this business a few years ago and it continues to set the bar on growth and margin expansion and we expect another strong performance from them in 2022.

Turning now to slide nine.

We are accelerating our innovation strategy.

Our relentless focus on innovation delivered 80, new products last year, and we're on pace to deliver over 100, new products in 2021.

In particular I'm pleased with the performance of our New road product range. This product has been very well received by our customers globally and positions Aesop to increase our market share in the light industrial equipment category.

We recently had a grand opening of our newly redesigned innovation facility in Gothenburg, I'm very proud of the detail passion and thought that went into the design one could feel the energy and excitement even though most attended the opening virtually <unk>.

To complement Gothenburg, we continue to invest in our R&D center in <unk> as a result, we have a strong funnel of new products to come.

With the recent acquisition of Octopus, we added capability of offline programming of robots strengthening our digital offerings.

Recently, we were able to win a key customer by providing a full workflow robotic solution that included our equipment filler metal and digital solutions.

This is a great example of a software acquisition that furthers, our strategic goals and increases our ability to gain more of our customers' wallet and.

In summary, we're confident in our ability to achieve our long term strategic goals of 3 billion processed in revenue <unk>.

<unk> plus percent in EBITDA segment margins and strong free cash flow.

With that let me hand, it over to Chris.

Thanks, Sean I'll start on slide 10.

We entered the third quarter with decreasing Covid pressures. This reversed in early August when increasing Delta Varian cases disrupted elective surgeries temporarily reducing expected revenues in our med Tech business. Despite this our total company achieved 20% sales growth with a small FX tailwind and six.

Points from acquisitions.

The Covid forces place to further strained on an already stressed global supply chain network, our operating teams executed effectively to supply customers, but this came at a higher cost, especially in freight and logistics that slowed our sequential margin expansion.

Our fab Tech business continued to successfully pass through its raw material cost inflation to customers protecting profit affecting gross margins.

Total company EBITDA margins grew 20 basis points, which was 90 basis points better before the effects from acquisitions.

Overall, we achieved adjusted EPS of <unk> 54 in the quarter toward the upper end of our guidance range, but a little lower than our trajectory before the COVID-19 resurgence.

This included a higher tax rate that we are expecting for the second half of the year due to profit mix changes in FX.

We had another strong quarter of free cash flow generating $68 million year.

Year to date, we are approaching $200 million and are well on our way to approximately $275 million for the year, excluding separation costs.

This includes higher inventory levels related to supply chain and logistics challenges.

Turning to slide 11, our <unk> business posted strong results this quarter.

Tom already covered the market commentary. So I'll highlight that are 23% total growth included volume growth this quarter over both 2020 and 2019 levels.

We are using dynamic customer pricing to stay on top of raw material inflation pressures and we expect to see a small amount of additional price running through in the fourth quarter based on actions already taken in the third quarter.

EBITDA margins were again at healthy levels up 180 basis points to 16, 5%.

Volume leverage and benefits from restructuring programs underpin this terrific performance and we had favorable timing on the resolution of some previously reserved matters that contributed about half of the improvement and won't recur in Q4.

On slide 12, our med Tech business grew by 14% over 2020, Q3 results, including organic sales per day growth of 3% excluding PPE.

The acquisitions are contributing as expected and are on solid pads for strong growth and healthy margin expansion.

This quarter's performance reflects at least 500 basis points of reduced organic growth from the delta varying impact on elective surgeries and related clinical and patient services.

Because of our high gross margins in this business. The revenue drag also impacted margins in the quarter as growth strengthens we expect strong volume leverage that will contribute to healthy margin expansion.

Our operating teams are pointed in the right direction to serve customers first and foremost.

They are working hard to overcome COVID-19, driven global supply chain constraints, which added approximately $3 million of costs this quarter versus last year's Q3.

This friction is likely to persist into at least the first half of 2022.

Included on this page is a chart that fuels apart the EBITDA performance progression this year to separate our organic performance versus acquisitions.

Q3 organic margin stepped up from Q2 levels, despite having approximately $20 million of sequentially lower revenues.

We expect even higher organic margins in Q4, as the Delta variant pressures moderate and as we benefit from seasonally higher revenues.

We expect our fast growing high gross margin acquisitions to become EBITDA accretive over the next three years, including the benefit from cost synergies.

Our outlook for the year is included on slide 13.

We started the year with an EPS forecast of $2 to $2 15.

As our performance strengthened throughout the first half of the year, we improved our outlook a few times and landed in July at $2 10 to $2 20.

Entering the fourth quarter, we expect the transitional impacts of Covid in our tax rate to keep it in this range shaping toward the lower end.

Our current forecast includes the continual gradual recovery of elective surgeries that we experienced in October as well as the current level of Covid driven friction in our supply chain.

We also expect the typical sequential seasonal revenue improvements in both of our businesses.

As noted earlier, our free cash flow performance remains on track for approximately $275 million this year before costs related to the separation.

Yes.

I'll conclude our prepared remarks on slide 14.

Our teams are performing very well this year in a difficult environment.

We are outperforming market growth levels and driving continuous operational improvements.

We've completed acquisitions to shape, the med tech business for faster growth and margin expansion in the coming years and the integrations are right on track.

Our two businesses continued to gather momentum as we approach the first quarter 2022 separation.

And our teams are excited and ready for their new futures.

And with that let's go ahead and open up the call for questions.

Alright. Thank you we will now begin the question and answer session. If you have a question. Please press Star then one on your Touchtone phone.

To be removed from the queue. Please press the pound sign are the hash key if youre using a speakerphone you may need to pick up the handset first.

Before pressing the numbers once again, if you have a question Star then one on your Touchtone phone.

Our first question.

Mr. Scott David of Malleus Research you May go ahead.

Thanks, operator, good morning, guys.

Hello, Scott good morning.

Curious on what steps are left in.

Just to get done to get to the finish line on the on the split.

Yeah. Thanks, Scott as you would imagine this has been a pretty well orchestrated effort by our team and we are well into the process here, we've talked about getting Johns team built out for the corporate support capabilities that he needs has already got of course, all the operating team and momentum there.

We're close to getting our board is fully built out as well, we've talked about capital structure and getting that aligned and so really at this point. It's just following some of the more typical steps that you would expect getting filings ready.

And and so on so we're.

We're right on track, we don't expect any significant challenges here as we approach the separation.

Okay, and then on the same line of questioning how many of those.

Physicians were able to fill internally.

At each of the.

Our senior positions or however, you guys want to define it to police to certain levels.

Yes, so first as we shared already shop and the leadership team of.

Saab.

Our.

Most of the road there are people that have been with us for a number of years like Kevin Johnson. The CFO, who you all are familiar with etsy with our IR leader before he was in this role and has been with the business for a number of years with the company for for many years. So that leadership team was mostly in place when we announced the separate.

<unk>.

And then there have been.

A few a few specific additional add there and then as far as the sort of corporate leadership support team.

<unk>.

A few roles there that have come from our Colfax team here.

And then there's been a fair amount of hiring as well and but it's been it's been great I think the talent that the team has been able to attract.

It really shows the excitement that people have for the opportunity ahead for <unk> as an independent company.

Okay, and just just real quickly it will price offset costs in med Tech and <unk>.

Alright.

The next question is from Andrew Open of Bank of America go ahead. Please.

Hi, good morning.

Chris Mike how are you from.

Yeah, just just a question of I know, it's sort of a tough one to answer but as we think about sort of met tech recovery, an elective procedures coming back based on your conversation.

What's your best guess, how just this progressive over the next six to nine months because I think this is unprecedented.

Unprecedented pause in growth for the industry, you guys doing as well as anybody but just what are you hearing from the channel in terms of how this recovery will progress in the first half of next year. Thank you.

Yes at first thanks for the question and a comment that we're doing as well as anybody I think we tried to share some some clear year to date organic Ada that hopefully lets you take a look at we really feel like we are outperforming nicely there.

In this environment and showing that we'll be able to outperform on the other side.

As far as the external environment.

We saw play out in the quarter was there was a pretty strong.

Pretty strong momentum there and that sort of June July period, and then near the end of July is when it started to be some pressure and so it really in August and September.

I think.

Data sets out there all suggests that elective surgery pulled back at least 5% some say.

More in as much as 10, but.

We feel like there was at least 5% pressure on elective surgery versus what we what we are seeing going into the into the quarter and expecting but then as as we got through the end of September and into October we're starting to see a little bit more activity and certainly there is.

Ziering intended plans by the surgeons to try to make it make up a little ground here in the fourth quarter and show a little bit of improvement as we go month to month, there's some limitations on that obviously the the compression was caused by some of the COVID-19 spikes around the country and in the regions that have lower back then Edison rates you see that.

The the more significant compression, but but the recovery is being limited by some other factors space in hospitals in operating rooms staffing is a new issue that's being talked about a lot.

Not being able to get enough staffing and so we do expect and we're seeing.

An improvement of elective surgery as we work through the fourth quarter. So that as we roll into next year, we can be kind of more in.

Getting to more normal levels.

And move forward and as we move through next year, we certainly feel like there is ground to be made up there's a lot of surgeries that we're not done in 2000, 22021 and need to be done and so the whole industry has some extra opportunity and I think that most of the conventional wisdom out there suggests that it's going to take a couple of years.

For that to be made up.

Given how much space and time et cetera would be needed and so that gives the opportunity for the industry to have little little extra market growth for each of the neck each of the coming years, and we expect it will be able to see that and continue to outperform it.

Okay. Just a follow up question given the number of the deals you guys are doing them give them pervasive.

Supply chain bottlenecks specific on the map tech business.

Can you just tell us how are you taking advantage of CBS or I guess his household ebs still CBS.

So.

We will it still CBS now.

Okay.

You guys using CBS two straight line.

Sort of interaction with your supply bass from sort of being able to get the product out the door in his eyes have particularly given the fact that you're bringing on number of acquisitions. Thanks, yeah. So.

Team had started started a really nice CBS journey already as we went through 2019, and we're starting to see real real benefits in terms of the service levels.

To customers and progress on productivity initiatives.

We are fully confident we're going to start to turn into some nice nice margin expansion as we move move forward.

That work continues but but for sure a lot of our CBS efforts have been redirected in the last few years here to focusing on customer service and.

Things like.

Our plant that produces embracing products.

Uses a CBS tools really every week to look look forward at the production forecast understand what they are going to be able to produce and where the limitations are in terms of different elements of the product supply and paredo that and then problem solved to be able to either.

Find a way to expedite the supply to be able to produce or redirect some of the resource in the facility in order to make other products. So that once we have product available.

They can access that so it's daily management as weekly management, it's root cause.

<unk> and it's certainly helping us a lot in terms of being able to serve customers. We think that in our competition through this period.

But.

But we're looking forward to the time, when we'll get those CBS tools driving productivity and margin expansion in the business.

<unk>, helping the teams to scramble for supply.

Thanks, so much.

Thanks, Andrew.

Yeah.

And our next question is from.

Kill Qian Donald with pollen and company go ahead. Please.

Hey, Good morning, this is Robert for Joe.

Just.

I'm wondering if you could talk about the implications of lower single pricing and how fast you all might have to get back some of the price increases.

Since we made recently.

Yeah. Thanks for that question Robert.

Seeing in the marketplace of that fuel tanks and relatively stable.

And so we will see where the price. So I think we've spoken about this before our intention as we expect when fuel prices go down that will give some price back but then we have other tools in our toolkit with CBS, where we talk about value different strategies around product lines streamlining et cetera.

Help us continue to hold some amount of that.

As we go through the years, so what I do expect that we will have some innovations new pricing.

As well as some give give backs related to steal prices declining.

Okay. That's helpful. Thank you.

And then just on the the Med Tech business just wondering.

How about procedure rates in the ambulatory procedures trended versus like the hospital based procedures is there any difference there.

And do you feel like you've picked up good share gains.

Yes, there is.

As we move through Covid.

Hospitals accelerated the pace of moving things into an ambulatory environment and the percent of procedures done in an ambulatory environment expanded at least temporarily and I think the expectation is that that that that balances back a little and then then then the AFC continues to outgrow.

We've tracked our business and portion of it that's in that ambulatory environment.

And we believe that our portion of the ambulatory environment is is more than the average industry amount and that it's been growing faster and so we do think that.

Success in that ambulatory environment has contributed to our share gains and we'd got strategy's aimed at making sure that.

Over time, we've got the right solutions, not just our implants, which set up well for the ambulatory environment, but also the full solution the workflow for that surgeon that helps them to efficiently do the procedure and a small footprint space and helps us to keep using that as a part of how we gained share in the market.

That's great. Thanks, so much for taking my questions.

Thanks Robert.

And the next question is from Chriss Snyder with you B S. Go ahead. Please.

Thank you. So the company has talked to kind of high single digit normalized organic growth for med Tech, but I was hoping for some more color or any movie targets. The company has an expected total growth.

Commentary and actions suggest you guys will continue to be active on M&A.

And then I guess I'll give you a different way to ask the same question is is there any kind of timeframe for the expected kind of 3 billion Med Tech revenue target, which the company has spoken though.

Yes, Thanks, Chris well I think first what I would say is we've talked about being able to drive to $2 billion pretty quickly and a lot of that is going to come from organic growth just starting from our pro forma coming out of this year and then.

A couple of years of good strong organic growth will get us a good ways towards that that $2 billion number.

And we certainly see ample.

Ample bolt ons and adjacencies that would be.

Opportunities to fill in the gap, there and to grow double digits through the through the coming years and get to that that $2 billion pretty quickly in terms of how we get from from two to 3 billion.

Certainly have the opportunity to grow nicely organically.

With the portfolio that we've been shaping and the strategies that we've been driving we have an opportunity to continue to do bolt ons and adjacencies like the ones that that we've been doing and then there are some some larger possibilities to think about within the orthopedics space. Some large attractive areas that were still not in.

And also adjacent to the orthopedics space.

It could be a part of how we make that journey from two to 3 billion always with a focus on making sure that we're we're getting great businesses.

That we are shaping our organic growth upwards to solidify that that high single digit consistent organic growth and we are shaping our gross margins upward because we got the organic growth and we've got the gross margins. We are very confident that we can drive the EBITDA margins up over time.

Appreciate that kind of I guess leads into my follow up on my Tech margins certainly understand the Covid was a pretty material dragging the quarter and M&A has been a margin headwind all year as expected but.

A legacy D. J O business is running down year on year, Despite similar top line and down pretty mature 19, despite higher top line at least by my math.

I know you guys called out supply chain as a headwind, but is there something else going on there that we should take note of that's driving that compression.

Yes beyond the acquisitions that you mentioned that are we try to isolate that that you can see the temporary impact of those acquisitions and we've already talked about how those are going to going to scale over time and some of the synergies on the math decides you set aside the acquisition in fact, there's there's really three factors there when we made some some meaningful investments.

Back as we worked through 19 that we've talked about to really get this business position for the for the future and get prepared to drive the kind of growth.

That that we're driving relative to industry now second operating leverage is important.

In that business.

And when we grow above mid single digits and in that high single digits organic range over time, there's a healthy amount of operating leverage that's going to contribute to the margins and through the past couple of years we've.

We've had limited.

Limited growth, there and that take that operating leverage.

Out of the equation and in shorter periods of time like recently.

When we expect to be at one level and then we wind up at a lower level it can be real headwind.

And then third Covid driven inefficiencies we're seeing.

Inflation.

We're seeing a lot of extra costs from from expediting. The inflation does not just product, but also freight and some of it is outbound trade the customers and we can look at how we pass through through policy et cetera, but but some of it also all the escalation in global freight rates related to supply chain pressures and those are expected to supply subside over time, but in the.

Meantime, that's extra extra costs coming through the system and beyond the inflation and expediting.

Production has been quite inefficient when I talked earlier about the challenge of week to week figuring out what are we going to make based on which supplies not come in the way they were supposed to and that that really has a pretty significant impact on the efficiency of how the plants run in and again we've chosen.

To focus on keeping customer service up.

And.

Bear the costs that go with that and so those are those are the three big factors that are affecting margins.

We think about the past the 25% going forward. So so yeah, we've got a little lower starting first place then we talked about earlier in the year. When we think about the past the 25% we've got an opportunity to recover that COVID-19 impact over time.

Terms of being able to manufacture more efficiently in terms of not having the excess expediting costs and things and and recovering that inflation, one way or the other whether we get it all through price or over time it subsides some.

Second we've got a chance to get that operating leverage and also productivity through CBS as we grow and that'll be a meaningful contributor contributor as well and third we got opportunities to.

Two scalar SG&A and to streamline our SG&A, we've had projects underway different initiatives streamlining our SG&A and we will continue to to focus there as well to make sure that that overall journey to 25% of secure and we're confident that that it is as I said, we've got the gross margin.

Will will be increasing that over time and we've also got the growth coming over time and so it will make sure that the bottomline comes with it.

I appreciate all that color. Thank you.

Alright, and next we have Jeff Hammond with keyboards.

Sorry, Keybanc cap markets. Please go ahead.

Good morning.

Good good to have you on the call maybe I'll ask you a question and go the other way I'm price can you just talk about.

Still kind of stabilizers hear what you think the wrap around pricing is for each sob into 22.

What what it'd take to you is that what we are we don't predict obviously, what happens with feel but we what I. What you know very well is that we've had a strong process and play.

We know exactly what to do and react to when few goes up or down and so my view on that particular pieces as I said earlier that steel has stabilized and some reasons, it's still going up.

We've got strong processes in place to react to that.

And then going forward, what I expect is that for that price cost these to continue to be neutral.

As we move forward.

Okay and then.

Maybe just on if we assume that there's kind of no re spikes in COVID-19 into twenty-two like what do you think is a reasonable kind of growth rate to think about her for PNR and recon individually as you as you move into 22.

Yeah, So our recon business.

It was.

So.

Maybe focus on the core growth our recon business was growing.

The double digits before we came into Covid.

And until we expect it to be able to come out the other side growing and healthy healthy double digits and then as we.

An ankle businesses or businesses that ticket.

As well and we've talked about the math is business as a business that will build from its mid single digit history up two of the double digits and so we do expect that overall recon portfolio to be able to grow in that.

In that double digits range.

As we come out and over time and on the PNR side those are our markets that.

Kind of in the in the 3% kind of range, we've been shaping the portfolio literally like the like your acquisition shapes us a little bit in a positive way and we will look for other ways to do that with with.

With bolt ons, but we do think that pinard business has been shaped up to where.

It's growing better than the market now right through Covid and so we do think on the other side were positioned to at least grow it at market rates in that business and.

And potentially higher than market rates and so if you if you put those together.

Certainly get the mid single digits plus.

And potentially high single digits.

Growth already on the other side of Covid versus a little bit further forward.

Okay, and then just click on for Chris.

We're getting closer to the to the split any thoughts on tax rates are tax structure for each of the businesses individually.

Yeah. Thanks, Jeff So we're continuing to work through all the tax structuring that it takes to enact tax free separation of the of the company and we've got.

Two great tax teams that are developing now to focus on where we can drive those rates longer term. So it's a little early for us to make definitive comments on that but I can tell you that absent any legislative change in the U S. R teams are going to be focused on maintaining rates.

At or below the current levels.

Okay. Thanks.

Oh, and we now have a question from Mason Jones.

Go ahead.

Good morning, everyone, Hey, Nathan.

I would like to ask a question on the pricing in Med Tech I think Matt during your prepared remarks, you said there were places you could get crossing places that you can't get pricing.

I assume that that's.

What to do with insurance reimbursement rates, but maybe for the industrial analysts on the call who don't understand those mechanisms as well you could describe a little bit about the process for getting those reimbursement rates increase that inflation goes through how long that might take et cetera.

Yeah sure. Yes, there is a portion of the business, there's a portion where where we are the biller and so we get the reimbursement rates.

And then there is.

Areas, where our direct direct customer the biller.

And.

Overtime in the industry. There is there is.

Constant reassessment.

Within within Medicare of what the right reimbursement rates are and and historically when there have been.

Inflationary periods.

Sometimes those rates have been been increased our sometimes some of the ongoing.

Yearly reductions that come through and some of the product lines have stabilized for for a few years before that continued.

And in some cases, that's something that that the industry.

Lobbies for and gives information for in some cases, it's the normal process.

They go go through that but.

There is certainly.

An opportunity for some of those reimbursement rates to change over time, and we think that will be part of the equation and then but then there is also another portion of this that is GPO contracts with hospitals and those those GPO contracts open up.

At different periods of time for different pieces of the business and again, the kind of historical trend on some of those GPO contract is that they typically go down each time that they that they open up and that's why this industry has a little bit of price down every year, but again, an inflationary periods in the past those GPL.

Contracts, sometimes stabilize or even go up for a period of time based on the arguments that flavors are able to make about the inflationary environment and so those are some of the other mechanisms beyond the straight price mechanism that will be coming through as we work through the next next couple of years and so I would expect.

That that.

The overall price cost equation for this business for the next couple of years is better than it is in normal years as we're pulling back.

What's what's happened over the course of these past few years.

So you think it takes like a year to two years.

For this to normalize.

Yeah, what I would say, we're certainly focused on trying to make sure that we get as much price through the systems as we can as fast as possible and offset as much as possible of of the inflationary impact that we use.

That we've born.

But but yeah I would also say that on the inflation part.

Within products, if the product costs don't go back down it will take a couple of years to fully fully more normalized now there are other inflationary things like expedited costs and higher freight costs that could change could change very quickly.

If things Stabilising, the global supply chains, and if there's any more access in terms of freight logistics you could see as we work through next year, you could see a sharper fall off in in some of these framed logistics costs.

That could be a faster pass through.

Thanks for that and then work with.

Chris.

You mentioned in quarter timing in Fabtech during the quarter could you give us some more details on what that was.

Yeah sure Nathan back.

Back in can be Tony we had some we had some customer and distribution challenges that we had to we had to reserve for them to or in some of that of course happening in the middle of all the all the COVID-19 timing there and our teams that are really good job of working through the related issues and getting to have a good answer.

Our expectations that we'd get to the other side of that more closer to the end of the year and the good news is we got there a little bit more quickly and so we wanted to highlight that just because it had to put a little bit of extra.

Positive impact on the.

Fabtech margins in the third quarter that you wouldn't expect to see as we progress into into queue for having said that we have every expectation that cute little margins and you said, we're going to be attractive in.

Relative to Mormons.

Great. Thanks, I'll pass it up.

Okay, and we now have Steve <unk> J P. Morgan go ahead. Please.

Hey, guys good morning.

Good morning, a Steve.

Can you just talk about.

You're kind of seeing an.

International markets and.

And the Fabtech business.

Any anything kind of out of China or anything like that and you could talk about.

Yeah. Thanks for that question, Steve I think what I have mentioned in my comments earlier as well we saw a really fast recovery in Asia as we came out of the Covid.

Period and restrictions what we are seeing is a stabilization and the growth rates.

And China is no different on that particular front, but other regions in Asia continued to seem to have a really strong growth profile, specifically as we speak about India and some of the other geographies there, but we are seeing a bit of a stabilization in our growth rates in China.

And how do you see that playing out and.

In the fourth quarter, and then going into next year.

Yeah, and so if what we have said does that all play in China has been really in places where we are innovation is appreciate it and when we add significant value. What we are seeing is that in places that we played and continues to be some tailwind and momentum on that particular sites that we're not seeing any downside.

And our position in China as as you know we play basically on the top tier of that particular marketplace in China.

Okay, great. Thanks, a lot.

And that concludes our Q&A session I will now turn the call back <unk>.

And I would now turn the call back to Mike May set for closing remarks go ahead. Please.

Thanks, everybody for joining our call today, and we look forward to catching up with you guys individually and have a good afternoon.

Thanks, everyone.

Thank you ladies and gentlemen. This concludes today's conference. Thank you for participating you may now disconnect.

Yeah.

Oh.

Yes.

Okay.

Okay.

Sure.

Yes.

Yeah.

Okay.

Okay.

Sure.

Okay.

[music].

[music].

[music].